Psychiatry & Neurology, Clinical Neurophysiology · Houston, TX
NPI
1558674747
Since 2010
Specialty
Psychiatry & Neurology, Clinical Neurophysiology
Code 2084N0600X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
8901 Boone Rd
Houston, TX, 77099
Phone (281) 454-0500
Groups this clinician bills Medicare through
Medicare paid, 2024
$24K
280 services
Medicare patients, 2024
88
Average age 66
Drug cost, 2024
$2.1M
657 prescriptions
Company payments, 2025
$799
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rajesh K Gupta was code 99215 (office e&m - established), 55 times for 35 patients. In total Rajesh K Gupta billed 280 services in 23 codes, and Medicare paid $24K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-09-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 55 | 35 | $115.90 | $6,374 |
| 99214 Office E&M - Established | Office | 45 | 30 | $75.33 | $3,390 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 43 | 33 | $12.12 | $521 |
By year: 2022 $23K for 1,097 services; 2023 $50K for 1,381 services; 2024 $24K for 280 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rajesh K Gupta prescribed most often to Medicare patients was Gabapentin, with 84 prescriptions and refills. In total Rajesh K Gupta wrote 657 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 84 | 193 | 28 | $1,614 |
| Baclofen Generic | 56 | 148 | 22 | $1,925 |
| Levetiracetam Generic | 37 | 105 | 13 | $1,081 |
| Kesimpta Pen Ofatumumab | 29 | 29 | Under 11 | $248K |
| Vumerity Diroximel Fumarate | 27 | 27 | Under 11 | $232K |
| Soliris Eculizumab | 25 | 25 | Under 11 | $1.3M |
| Pregabalin Generic | 25 | 53 | Under 11 | $4,246 |
| Memantine Hcl Generic | 20 | 36 | Under 11 | $435 |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | 20 | 20 | Under 11 | $69K |
| Duloxetine Hcl Generic | 19 | 44 | Under 11 | $247 |
| Tizanidine Hcl Generic | 19 | 29 | Under 11 | $293 |
| Pyridostigmine Bromide Generic | 14 | 30 | Under 11 | $1,853 |
| Amantadine Amantadine Hcl | 13 | 17 | Under 11 | $278 |
| Nurtec Odt Rimegepant Sulfate | 12 | 12 | Under 11 | $22K |
| Hydroxyzine Hcl Generic | 12 | 12 | Under 11 | $33 |
Brand drugs: - claims; generic drugs: 501 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rajesh K Gupta $799 ($799 in general payments such as food, travel and fees) from 17 companies. The largest payer was UCB, Inc. with $133.
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. UCB.BR | 5 | $133 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $128 |
| Alexion Pharmaceuticals, Inc. AZN | 4 | $102 |
| Janssen Biotech, Inc. JNJ | 4 | $89.46 |
| TG Therapeutics, Inc. TGTX | 3 | $88.6 |
| Argenx US, Inc. ARGX | 2 | $63.33 |
| Vanda Pharmaceuticals Inc. VNDA | 1 | $27.83 |
| Abbvie Inc. ABBV | 1 | $25.12 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $24.96 |
| Biogen, Inc. BIIB | 1 | $22.77 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.